NC
CATX icon

nVerses Capital’s Perspective Therapeutics CATX Stock Holding History

nVerses Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,420
Closed -$31.4K – 373
2025
Q4 		$31.4K Buy
+11,420
New +$32.6K 0.07% 193
2024
Q4 		– Sell
-4,300
Closed -$57.4K – 141
2024
Q3 		$57.4K Buy
+4,300
New +$57.2K 0.03% 597

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

nVerses Capital's CATX Position: Q1 2026 in Review

nVerses Capital sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 11,420 shares — an estimated $31.4K sold.

nVerses Capital first reported a position in CATX in Q3 2024 and held it in 2 quarters. The position peaked at $57.4K in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • nVerses Capital reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • nVerses Capital sold 11,420 Perspective Therapeutics shares in Q1 2026, an estimated $31.4K.
  • nVerses Capital first reported a position in Perspective Therapeutics in Q3 2024 and held it in 2 quarters.
  • nVerses Capital's Perspective Therapeutics position peaked at $57.4K in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on nVerses Capital's 13F filing for Q1 2026, filed 13 May 2026.